Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 8

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 8
---
 of the transaction, we changed our name from “Aadi Bioscience, Inc.” to “Whitehawk Therapeutics, Inc.”

Since March 2025, our principal executive offices are located at 2 Headquarters Plaza, East Building,
11 Floor, Morristown, NJ 07960. Prior to March 2025, our principal executive offices were located at 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California 90272. We maintain a
website at www.whitehawktx.com, to which we regularly post copies of our press releases as well as

S-5

additional information about us. Our filings with the Securities and Exchange Commission (the “SEC”) will be available free of charge through the website as soon as reasonably
practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this prospectus or any of our other filings with the SEC unless specifically incorporated herein by
reference. In addition, our filings with the SEC may be accessed through the SEC’s Electronic Data Gathering, Analysis, and Retrieval system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking
statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.

S-6

THE OFFERING

| Common stock offered by us | Shares of our common stock having an aggregate offering price of up to $75,000,000. |

| Common stock outstanding after this offering | Up to 73,382,006 shares, assuming sales at a price of $1.54 per share, which was the closing price of our common stock on the Nasdaq Capital Market on April 22, 2025. The actual number of shares issued will vary depending on the sales 
 price under this offering.                                                                                                                                                                                                                 |

| Plan of Distribution | “At the market offering” that may be made from time to time through our sales agent, TD Cowen and Company, LLC. See “Plan of Distribution” on page S-13. |

| Use of Proceeds | We intend to use the net proceeds from this offering, if any, for general corporate purposes, which may include, among other things, working capital and funding research and development, and capital expenditures, including the future preclinical 
 and clinical development of the ADC Therapies. See